Open AccessClinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively
Author(s) -
Fabrizio Bonelli,
Antonella Sarasini,
Claudia Zierold,
Mariella Calleri,
Antonella Bonetti,
Chiara Vismara,
Frank Blocki,
L. Pallavicini,
Alberto Chinali,
Daniela Campisi,
Elena Percivalle,
Anna Pia DiNapoli,
Carlo Federico Perno,
Fausto Baldanti
Publication year - 2020
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.01224-20
Subject(s) - serology , covid-19 , medicine , virology , antibody , immunology , neutralizing antibody , pandemic , coronavirus , immunoglobulin g , pathology , disease , infectious disease (medical specialty) , outbreak
In the coronavirus (CoV) disease 2019 (COVID-19) pandemic, highly selective serological testing is essential to define exposure to severe acute respiratory syndrome CoV 2 (SARS-CoV-2). Many tests have been developed, yet with variable speeds to first results, and are of unknown quality, particularly when considering the prediction of neutralizing capacity. The LIAISON SARS-CoV-2 S1/S2 IgG assay was designed to measure antibodies against the SARS-CoV-2 native S1/S2 proteins in a standardized automated chemiluminescence assay.